Drug Profile
Research programme: anti-CD47 antibodies - Essen BioScience
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Essen BioScience
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action CD47 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 05 Apr 2017 Preclinical trials in Cancer in USA prior to April 2017 (unspecified route)